Hsiou-ting Kuo

Title: Hsiou-ting Kuo: Innovator in Theranostic Compounds

Introduction

Hsiou-ting Kuo is a prominent inventor based in Vancouver, Canada. He has made significant contributions to the field of theranostic compounds, particularly in the development of innovative molecular complexes. With a total of 2 patents, Kuo's work focuses on advancing cancer treatment and imaging techniques.

Latest Patents

Kuo's latest patents include groundbreaking inventions such as "Dual mode 18F-labelled theranostic compounds and uses thereof." This patent describes a compound or molecular complex that features a metal chelator designed for chelation with either a radioactive or non-radioactive isotope. Additionally, it includes a trifluoroborate-containing moiety configured for F/F exchange or a precursor thereof, along with an optional cell-targeting domain. Another notable patent is for "18/19F-labelled compounds which target the prostate-specific membrane antigen." This disclosure introduces novel compounds that comprise a zwitterionic trifluoroborate prosthetic group, specifically targeting prostate-specific membrane antigen (PSMA) in prostate cancer. The compounds are characterized by a specific formula that includes various functional groups aimed at enhancing their efficacy in imaging and treating PSMA-expressing cancers.

Career Highlights

Throughout his career, Hsiou-ting Kuo has worked with esteemed institutions such as the University of British Columbia and the British Columbia Cancer Agency. His research has significantly impacted the field of cancer diagnostics and therapeutics, showcasing his dedication to improving patient outcomes through innovative solutions.

Collaborations

Kuo has collaborated with notable professionals in his field, including David Perrin. These partnerships have fostered advancements in research and development, further enhancing the impact of his work.

Conclusion

Hsiou-ting Kuo's contributions to the field of theranostic compounds exemplify his commitment to innovation in cancer treatment. His patents and collaborations reflect a dedication to advancing medical science and improving patient care.